Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer

COMPORT is a multicenter phase II clinical trial evaluating a personalized approach to postoperative radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC). The study investigates whether a risk-adapted, compartmentalized radiotherapy strategy can safely reduce the treatment volume, and thus the side effects, without increasing the risk of tumor recurrence. Eligible patients are those with surgically treated cancers of the oral cavity, oropharynx, larynx, or hypopharynx who have a standard indication for postoperative radiotherapy. The primary outcome is the rate of recurrence in anatomical compartments that would normally be irradiated but are intentionally omitted in this study. COMPORT aims to generate high-level evidence to support a more personalized and less toxic standard of care in postoperative head and neck cancer management.

NCT Number	NCT07058805
Lead Sponsor	Olgun Elicin Collaborators: Clinical Trials Unit, Bern, Switzerland, Fond'action contre le cancer, University Hospital, Zürich, University Hospital, Basel, Switzerland, Kantonsspital Aarau, Oncology Institute of Southern Switzerland, Insel Gruppe AG, University Hospital Bern
Conditions	Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Enrollment	50 participants
Start Date	2026-01-15
Primary Completion	2029-01 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-05-06